Top Abstract Purchase Related
Home
>
Node
>
Subnode

The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine')

Kitamura, S.

Pharmatherapeutica 2(5): 330-336

1980

ISSN/ISBN: 0308-051X
PMID: 7433473
Document Number: 161539
A study was carried out in 40 patients with bronchial asthma to assess the therapeutic effect of co-dergocrine ('Hydergine'), an alpha-adrenergic receptor blocking agent, when added to their standard treatment with a beta-adrenergic receptor stimulant and aminophylline. Co-dergocrine administration (3 to 6 mg per day) brought about marked improvement in 25% and an improvement in 55% of the patients. The results suggest that co-dergocrine could be a useful drug when combined with other bronchodilators in the treatment of bronchial asthma.

Document emailed within 1 workday
Secure & encrypted payments

Calvagno, M. 1982: Usefulness of an alpha-adrenergic blocking agent (nicergoline) in the treatment of diabetic angiopathy of lower limbs Il Farmaco; Edizione Pratica 37(6): 200-205
Renouard, A.; Widdowson, P.S.; Millan, M.J. 1994: Multiple alpha 2 adrenergic receptor subtypes. I. Comparison of [3H]RX821002-labeled rat R alpha-2A adrenergic receptors in cerebral cortex to human H alpha2A adrenergic receptor and other populations of alpha-2 adrenergic subtypes Journal of Pharmacology and Experimental Therapeutics 270(3): 946-957
Gupta, S.; Ternberg, J.L.; Weldon, V.V.; Pagliara, A.S. 1973: Alpha-adrenergic blocking agent in childhood pheochromocytoma Surgery 74(4): 545-550
Miki, H. 1983: Effect of befunolol ophthalmic solution, alpha, beta-adrenergic blocking agent, on secondary glaucoma Nippon Ganka Gakkai Zasshi 87(1): 1-13
Ritter, M.M.; Richter, W.O.; Schwandt, P. 1992: Metabolic consequences of long-term antihypertensive treatment with co-dergocrine mesylate/nifedipine in high age groups Arzneimittel-Forschung 42(3): 311-313
Huidobro-Toro, J.P.; Carpi, A. 1976: Selective blocking properties of chloro acetyl catechol (CAC) on the alpha-adrenergic receptor Archives Internationales de Pharmacodynamie et de Therapie 222(2): 180-192
Zebrowska-Lupina, I. 1978: Studies on the mechanisms of central action of alpha-adrenergic receptor blocking agents Polish Journal of Pharmacology and Pharmacy 30(4): 455-458
Honda, Y.; Masuda, Y.; Yoshida, T.; Sato, F.; Kurokawa, M.; Hosoki, K. 1995: Studies on calcium antagonistic and alpha 1-adrenergic receptor blocking activities of monatepil maleate, its metabolites and their enantiomers Arzneimittel-Forschung 45(10): 1057-1060
Musial, W.; Tracz, W.; Krzemińska-Pakula, M. 1971: New adrenergic blocking agent Visken (LB-46) in the treatment of chronic coronary disease Polski Tygodnik Lekarski 26(22): 834-836
Shen, J.Q. 1981: Atenolol, a new beta-adrenergic blocking agent, in treatment of hypertension: therapeutic effect and hemodynamic changes Zhonghua Xin Xue Guan Bing Za Zhi 9(2): 94-98
Dufour, R.; Scazziga, B.; Schelling, J.L. 1970: Acute circulatory effects of a beta adrenergic blocking agent (LB 46) in patients with sympathetic overstimulation Internationale Zeitschrift für Klinische Pharmakologie Therapie und Toxikologie. International Journal of Clinical Pharmacology Therapy and Toxicology 4(1): 145-147
Price, D.T.; Chari, R.S.; Berkowitz, D.E.; Meyers, W.C.; Schwinn, D.A. 1994: Expression of alpha 1-adrenergic receptor subtype mRNA in rat tissues and human SK-N-MC neuronal cells: implications for alpha 1-adrenergic receptor subtype classification Molecular Pharmacology 46(2): 221-226
Lydtin, H. 1975: The significance of beta-adrenergic receptor blocking agents in the treatment of hypertension Die Medizinische Welt 6(35): 1487-1492
Batlle, F.; Carreño, C.A.; Guetta, N.J.; Vassolo, E.; Bertolasi, C.A. 1970: Treatment of cardiac arrhythmias using a beta adrenergic receptor blocking drug Prensa Medica Argentina 57(38): 1801-1808
Metelitsa, V.I.; Filatova, N.P. 1990: Role of a beta adrenergic blocking agent nadolol (corgard) in prevention of arterial hypertension: a 6-month treatment (cooperative study) Kardiologiia 30(5): 8-14
Wang, J.; Li, J.; Lu, R.; Wang, J.-M. 2002: Treatment of external RF hyperthermia combining with alpha 1-adrenergic receptor blocker for patients with prostatodynia and chronic non-bacterial prostatitis Zhonghua Nan Ke Xue 8(1): 48-50
Bylund, D.B.; Ray-Prenger, C. 1989: Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype Journal of Pharmacology and Experimental Therapeutics 251(2): 640-644
Lorenz, W.; Lomasney, J.W.; Collins, S.; Regan, J.W.; Caron, M.G.; Lefkowitz, R.J. 1990: Expression of three alpha 2-adrenergic receptor subtypes in rat tissues: implications for alpha 2 receptor classification Molecular Pharmacology 38(5): 599-603
Price, D.T.; Lefkowitz, R.J.; Caron, M.G.; Berkowitz, D.; Schwinn, D.A. 1994: Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology Molecular Pharmacology 45(2): 171-175
Miyagishi, A.; Nakahara, H.; Hara, Y. 1984: Adrenoceptor blocking effects of arotinolol, a new combined alpha- and beta-adrenoceptor blocking agent Archives Internationales de Pharmacodynamie et de Therapie 271(2): 249-262